Anti Cd 20 Ocrevus denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Issue a "Not FDA-Approved" Denial for Ocrelizumab

Ocrelizumab (Ocrevus) carries FDA approval for defined forms of multiple sclerosis. A "not FDA-approved" denial from Humana in this context typically reflects one of three scenarios: the claim was coded to an indication that is not listed in the FDA-approved labeling; the plan's system flagged the drug against the wrong patient profile; or there is an administrative or coding error in the submission. Regardless of the cause, this type of denial is one of the most straightforwardly correctable because FDA approval status is a verifiable matter of public record.

## Why This Denial Is Appealable

If your prescription is for an FDA-approved indication and the documentation confirms it, the denial is factually unsupportable. Humana is required to explain, in writing, exactly which indication or use it considers unapproved. Once you have that explanation, the appeal can directly confront the factual basis of the denial. If the denial stems from a coding error, a corrected claim submission may resolve the issue without a full clinical appeal.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 guarantee a full-and-fair internal review. File within the deadline stated in your denial letter.
• External review: After exhausting internal remedies, independent external review is available under ACA §2719, generally within approximately four months of final internal denial. An external reviewer must apply objective evidence standards — not solely Humana's internal policy.
• Expedited track: If ongoing treatment is interrupted, request expedited review; decisions are typically required within 72 hours.

## Documentation to Gather

1. Current FDA prescribing information for ocrelizumab — obtain the full label and highlight the specific approved indication that matches your diagnosis. 2. Prescriber confirmation letter — a brief letter from your neurologist confirming that the prescription is for an FDA-approved indication, citing the labeling. 3. Diagnosis records — neurologist notes and diagnostic workup confirming your MS diagnosis and classification. 4. Claim and coding review — ask your prescriber's billing staff to confirm that the diagnosis and drug codes on the submitted claim are accurate. 5. Humana's written denial with the specific basis — you are entitled to a full explanation; request it before drafting the appeal.

## Criteria-Mapping Approach

In your appeal, present a two-column table. Left column: Humana's stated reason for the "not FDA-approved" determination. Right column: the corresponding entry in the FDA-approved labeling, paired with your prescriber's documentation of the matching diagnosis. This direct mapping eliminates the factual basis of the denial and requires Humana's reviewer to either accept the evidence or provide a new, specific rationale — which then becomes the subject of a separate appeal or external review.

## Next Step

Before writing a full clinical appeal, call Humana's provider services line and ask for the specific ICD or NDC code that triggered the denial. Often, this reveals a coding mismatch that can be corrected administratively, avoiding the need for a full appeal altogether.